Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

Time For Oral Incretins To Prove Their Worth

Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.

Clinical Trials Metabolic Disorders

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.

Commercial Companies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

Commercial Clinical Trials

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Clinical Trials Business Strategies

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Companies Financing

Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Clinical Trials Companies

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

Business Strategies Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

 In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.

Commercial Clinical Trials

Stock Watch: Where Novo And Lilly Lead, Others Follow

AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.

Stock Watch Sales & Earnings

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?

Clinical Trials Financing

AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.

Business Strategies Clinical Trials

Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?

Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.

Commercial Companies
See All
UsernamePublicRestriction

Register